Interferon alfa-2b
- Generic Name
- Interferon alfa-2b
- Brand Names
- Intron A
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 98530-12-2
- Unique Ingredient Identifier
- 43K1W2T1M6
- Background
Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.
- Indication
For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.
- Associated Conditions
- Chronic Hepatitis B Infection, Chronic Hepatitis C Virus (HCV) Infection, Condylomata Acuminata (External), Follicular Non-Hodgkin's Lymphoma, Hairy Cell Leukemia (HCL), Kaposi's Sarcoma, Malignant Melanoma
- Associated Therapies
- -
Evaluate the Efficacy and Safety of Interferon-α Combined With ATO in the Treatment of Arsenic-resistant APL
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Zhejiang Provincial People's Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT06450145
- Locations
- 🇨🇳
First Affiliated Hospital of Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
Combination Therapy With Interferon Plus Interleukin 2 and Hepatitis B Vaccine in Chronic Hepatitis B Patients
- Conditions
- Interventions
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2018-05-09
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 94
- Registration Number
- NCT02360592
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳BeiJing YouAn Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳First Hospital, Beijing University, Beijing, Beijing, China
Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2022-01-13
- Lead Sponsor
- Polish Lymphoma Research Group
- Target Recruit Count
- 100
- Registration Number
- NCT02323659
- Locations
- 🇵🇱
Centrum Onkologii im. prof. F. Łukaszczyka, Bydgoszcz, Poland
Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia
- Conditions
- Interventions
- First Posted Date
- 2014-07-24
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Coordinación de Investigación en Salud, Mexico
- Target Recruit Count
- 18
- Registration Number
- NCT02199327
- Locations
- 🇲🇽
IMSS Centro Médico de Occidente, Guadalajara, Jalisco, Mexico
Interferon α for the Therapy of Minimal Residual Disease
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2018-06-07
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 81
- Registration Number
- NCT02185261
- Locations
- 🇨🇳
Peking University Institute of Hematology,Beijing, Beijing, Beijing, China
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 158
- Registration Number
- NCT02174172
- Locations
- 🇺🇸
HonorHealth Research Institute - Bisgrove, Scottsdale, Arizona, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- David Bartlett
- Target Recruit Count
- 64
- Registration Number
- NCT02151448
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Randomized Phase III of PRRT Versus Interferon
- Conditions
- Interventions
- First Posted Date
- 2013-05-23
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- Jules Bordet Institute
- Registration Number
- NCT01860742
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
🇧🇪Jules Bordet Institute, Brussels, Belgium
Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-07-13
- Last Posted Date
- 2014-01-07
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT01639885
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
- First Posted Date
- 2012-05-22
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT01603212
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.